Abstract
Deregulation of the tumor suppressor p27kip1 (p27) has been implicated in a variety of human cancers, suggesting it might be a viable therapeutic target. Developing p27-specific intervention strategies requires understanding its role and regulation in normal and pathologic states. Although p27 has been extensively characterized as an inhibitor of cyclin-dependent kinases, disruption of this function is inadequate to explain its role in tumorigenesis. A more comprehensive understanding of p27 biology would facilitate development of therapeutic responses to p27 disruption in human cancers.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 249-259 |
| Number of pages | 11 |
| Journal | Progress in cell cycle research |
| Volume | 5 |
| State | Published - 2003 |
